BioIVT to Host Drug Discovery Webinar on Gene Silencing Using siRNA In Hepatocyte Co-cultures
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a drug discovery webinar that will discuss how small interfering RNA (siRNA) molecules can be used to selectively suppress hepatic genes in an in vitro liver model and advance the development of small molecule and nucleic acid therapies.
BioIVT’s HEPATOPAC® Technology is used to form a micro-patterned co-culture of primary hepatocytes and non-parenchymal stromal cells which maintain in vivo-like liver function and metabolic activity for up to four weeks.
Liliana Mancio Silva, PharmD, PhD, research associate at the French National Institute of Health and Medical Research (INSERM) will present the webinar, entitled “Improving Drug Discovery by Nucleic Acid Delivery in Micropatterned Co-cultured Hepatocytes,” at 11 a.m. ET on Dec. 11.
Prior to joining INSERM, Dr. Silva was a research scientist in Prof. Sangeeta Bhatia’s laboratory at Massachusetts Institute of Technology, where she worked on nucleic acid delivery systems to target hepatocytes and impact human liver genetic and infectious diseases.
Dr. Silva will discuss the use of several nucleic acid delivery systems in the HEPATOPAC model. She will also describe how to achieve robust, long-lasting gene silencing via siRNA molecules, deliver siRNA-mediated modification of hepatocyte drug metabolism, and assess hepatic-targeted nucleic acid therapies.
Dr. Silva’s presentation was so well received at BioIVT’s recent HEPATOPAC User Group Meeting that the team asked her to share it with the broader research community.
Interested persons can register for this complimentary, one-hour webinar at https://info.bioivt.com/sirna-wbr-reg.
BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.